Shares of Eli Lilly (LLY) were higher Tuesday after the drug manufacturing company announced that starting January first of next year, customers will be able to purchase insulin at a discount of up to 40% amid a partnership with Express Scripts (ESRX) . The deal is intended to help people who have no insurance or high deductible plans. Users can use the Blink Health online pharmacy platform to activate the discounts. The vice president of Lilly Diabetes, said that, "this platform will effectively allow Lilly to lower our insulin retail prices for users of this platform while not affecting the reimbursement system for other people living with diabetes." TheStreet's Alicia McElhaney highlights that Eli Lilly's pricing change comes amid the backlash Mylan (MYL) faced, when it hiked its EpiPen drug earlier this year.
More from Video
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Is Renewable Energy the Defensive Stock Opportunity You're Missing
AMSC CEO discusses that and China challenges.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Real Money Video Wrap: Citi Surges as View of Stability Saves Sentiment
Citi overcame a mixed print to send its stock surging on Monday.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.